1
|
Dai Y, Wei X, Jiang T, Wang Q, Li Y, Ruan N, Luo P, Huang J, Yang Y, Yan Q, Zhang C, Liu Y. Ferroptosis in age-related vascular diseases: Molecular mechanisms and innovative therapeutic strategies. Biomed Pharmacother 2024; 173:116356. [PMID: 38428313 DOI: 10.1016/j.biopha.2024.116356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 02/19/2024] [Accepted: 02/26/2024] [Indexed: 03/03/2024] Open
Abstract
Aging, an inevitable aspect of human existence, serves as one of the predominant risk factors for vascular diseases. Delving into the mystery of vascular disease's pathophysiology, the profound involvement of programmed cell death (PCD) has been extensively demonstrated. PCD is a fundamental biological process that plays a crucial role in both normal physiology and pathology, including a recently discovered form, ferroptosis. Ferroptosis is characterized by its reliance on iron and lipid peroxidation, and its significant involvement in vascular disease pathophysiology has been increasingly acknowledged. This phenomenon not only offers a promising therapeutic target but also deepens our understanding of the complex relationship between ferroptosis and age-related vascular diseases. Consequently, this article aims to thoroughly review the mechanisms that enable the effective control and inhibition of ferroptosis. It focuses on genetic and pharmacological interventions, with the goal of developing innovative therapeutic strategies to combat age-related vascular diseases.
Collapse
Affiliation(s)
- Yue Dai
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Xiuxian Wei
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Tao Jiang
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Qian Wang
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Yi Li
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Nan Ruan
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Pengcheng Luo
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Jingwen Huang
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Nursing, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Yan Yang
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Qi Yan
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Cuntai Zhang
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Yu Liu
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
| |
Collapse
|
2
|
Vijayakumar STV, Narayanaswamy R, Prabhakaran VS. In Silico Analysis of Selected Mikania Constituents As Human HMG-CoA Reductase, Human Inducible Nitric Oxide Synthase, and Human Squalene Synthase Inhibitory Agents. Cureus 2024; 16:e55110. [PMID: 38558754 PMCID: PMC10979245 DOI: 10.7759/cureus.55110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Accepted: 02/27/2024] [Indexed: 04/04/2024] Open
Abstract
Background Numerous pharmacological activities have been reportedin Mikania species. In the present investigation, we aimed to evaluate 26 selected constituents of Mikania as potent inhibitory agents of human HMG-CoA reductase (hHMGR), human inducible nitric oxide synthase (hiNOS), and human squalene synthase (hSQS) using the in silico method. Methodology Twenty-six selected constituents of Mikania were investigated based on the docking behavior of three target enzymes, namely hHMGR, hiNOS, and hSQS, using the Cdocker method (Discovery Studio® 3.1, Accelrys, Inc., San Diego, CA). Results Docking analysis showed that methyl-3,5-di-O-caffeoyl quinate (MCQ) has the maximum binding energy (BE) (-39.63, -50.65, and -58.56 kcal/mol) with hHMGR, hiNOS, and hSQS enzymes. On the other hand, six ligands (kaurenoic acid (KAA), stigmasterol (SS), grandifloric acid (GA), kaurenol (KA), spathlenol (SP), and taraxerol (TA)) of Mikania failed to dock with either of the target enzymes (hHMGR, hiNOS, or hSQS). Conclusions The findings of the current study provide new insight regarding 26 selected ligands of Mikania as potent inhibitory agents of hHMGR, hiNOS, and hSQS.
Collapse
Affiliation(s)
- Sri Tharany Vahsh Vijayakumar
- Biochemistry, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (Deemed to be University), Chennai, IND
| | - Radhakrishnan Narayanaswamy
- Biochemistry, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (Deemed to be University), Chennai, IND
| | - Vasantha-Srinivasan Prabhakaran
- Bioinformatics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (Deemed to be University), Chennai, IND
| |
Collapse
|
3
|
Liang Y, Besch-Williford C, Hyder SM. The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth. Breast Cancer Res Treat 2022; 192:53-63. [PMID: 35037188 DOI: 10.1007/s10549-021-06487-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Accepted: 12/04/2021] [Indexed: 02/07/2023]
Abstract
PURPOSE Most hormone-dependent human breast cancers develop resistance to anti-hormone therapy over time. Our goal was to identify novel treatment strategies to avoid this drug resistance and thereby control hormone-dependent breast cancer. METHODS Sulforhodamine B assays were used to measure viability of cultured human breast-cancer cells. BT-474 cell tumor xenografts in nude mice were used to evaluate tumor growth. Immunohistochemistry was used to assess estrogen-receptor and angiogenesis-marker expression, as well as apoptosis, in tumor-xenograft tissues. RESULTS MCF-7 and BT-474 breast-cancer cells treated with either RO 48-8071 <[4'-[6-(Allylmethylamino)hexyloxy]-4-bromo-2'-fluorobenzophenone fumarate] [RO]; a small-molecule inhibitor of oxidosqualene cyclase, a key enzyme in cholesterol biosynthesis> or liquiritigenin [LQ; an estrogen receptor (ER) β agonist] exhibited significantly reduced viability in vitro. RO + LQ treatment further significantly reduced cell viability. Administration of RO, LQ, or RO + LQ significantly inhibited growth of BT-474 tumor xenografts in vivo. RO, LQ, or RO + LQ reduced ERα but induced ER β expression in tumor xenografts. Both compounds significantly reduced angiogenesis-marker expression and increased apoptosis in tumor xenografts; use of RO + LQ significantly enhanced the effects observed with a single agent. CONCLUSION The ERβ ligand LQ significantly enhanced the inhibition of breast-cancer cell viability and tumor-xenograft growth by RO. The anti-tumor properties of RO may in part be due to an off-target effect that reduces ERα and increases ERβ, the latter of which can then interact with LQ to promote anti-proliferative effects. The RO + LQ combination may have value when considering novel treatment strategies for hormone-dependent breast cancer.
Collapse
Affiliation(s)
- Yayun Liang
- Dalton Cardiovascular Research Center, University of Missouri, 134 Research Park Drive, Columbia, MO, 65211, USA.,Department of Biomedical Sciences, University of Missouri, Columbia, MO, 65211, USA
| | | | - Salman M Hyder
- Dalton Cardiovascular Research Center, University of Missouri, 134 Research Park Drive, Columbia, MO, 65211, USA. .,Department of Biomedical Sciences, University of Missouri, Columbia, MO, 65211, USA.
| |
Collapse
|
4
|
Ding Z, Gu Y, Huang D, Zhou H, Zhu T, Luo X, Zhang S, Zhang S, Qian Y. Cholesterol biosynthesis inhibitor RO 48‑8071 inhibits pancreatic ductal adenocarcinoma cell viability by deactivating the JNK and ERK/MAPK signaling pathway. Mol Med Rep 2021; 24:828. [PMID: 34590153 PMCID: PMC8503744 DOI: 10.3892/mmr.2021.12468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Accepted: 07/12/2021] [Indexed: 11/08/2022] Open
Abstract
The morbidity and mortality of pancreatic cancer have been continuously increasing, causing seven deaths per 100,000 individuals/year. At present, effective therapies are severely lacking, thus, highlighting the importance of developing novel therapeutic approaches. The present study aimed to investigate the inhibitory roles of the 2,3-oxidosqualene cyclase inhibitor, RO 48-8071 (RO), on pancreatic ductal adenocarcinoma. RO was used to treat the pancreatic cancer cell line (PANC-1) in vitro to examine the effects of RO on cell viability, as well as to determine its potential molecular mechanism. Moreover, experiments in a xenograft model of subcutaneous tumors generated by injecting PANC-1 cells hypodermically into nude mice were performed to observe the inhibition of RO on tumor growth. It was found that RO inhibited PANC-1 cell viability when treatment was given for 24, 48 and 72 h. The in vivo study demonstrated that RO markedly inhibited subcutaneous tumor growth in nude mice. Further studies revealed that RO could induce cell cycle arrest in the G1 phase by regulating p27, cyclin B1 and cyclin E expression to inhibit PANC-1 cell viability. Moreover, RO inactivated the JNK and ERK MAPK signaling pathway by decreasing the phosphorylation levels of JNK and ERK. Collectively, the present study demonstrated that RO served anti-pancreatic cancer roles in vitro and in vivo, which may provide new ideas and facilitate the development of novel treatment options for pancreatic cancer.
Collapse
Affiliation(s)
- Zhen Ding
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
| | - Yanan Gu
- Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, Anhui 230032, P.R. China
| | - Dake Huang
- Comprehensive Laboratory, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui 230032, P.R. China
| | - Hong Zhou
- Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, Anhui 230032, P.R. China
| | - Tingting Zhu
- Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, Anhui 230032, P.R. China
| | - Xin Luo
- Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, Anhui 230032, P.R. China
| | - Sumei Zhang
- Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, Anhui 230032, P.R. China
| | - Shengquan Zhang
- Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, Anhui 230032, P.R. China
| | - Yeben Qian
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
| |
Collapse
|
5
|
Giacomini I, Gianfanti F, Desbats MA, Orso G, Berretta M, Prayer-Galetti T, Ragazzi E, Cocetta V. Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy. Front Oncol 2021; 11:682911. [PMID: 34109128 PMCID: PMC8181394 DOI: 10.3389/fonc.2021.682911] [Citation(s) in RCA: 61] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Accepted: 05/06/2021] [Indexed: 12/14/2022] Open
Abstract
Cholesterol is a ubiquitous sterol with many biological functions, which are crucial for proper cellular signaling and physiology. Indeed, cholesterol is essential in maintaining membrane physical properties, while its metabolism is involved in bile acid production and steroid hormone biosynthesis. Additionally, isoprenoids metabolites of the mevalonate pathway support protein-prenylation and dolichol, ubiquinone and the heme a biosynthesis. Cancer cells rely on cholesterol to satisfy their increased nutrient demands and to support their uncontrolled growth, thus promoting tumor development and progression. Indeed, transformed cells reprogram cholesterol metabolism either by increasing its uptake and de novo biosynthesis, or deregulating the efflux. Alternatively, tumor can efficiently accumulate cholesterol into lipid droplets and deeply modify the activity of key cholesterol homeostasis regulators. In light of these considerations, altered pathways of cholesterol metabolism might represent intriguing pharmacological targets for the development of exploitable strategies in the context of cancer therapy. Thus, this work aims to discuss the emerging evidence of in vitro and in vivo studies, as well as clinical trials, on the role of cholesterol pathways in the treatment of cancer, starting from already available cholesterol-lowering drugs (statins or fibrates), and moving towards novel potential pharmacological inhibitors or selective target modulators.
Collapse
Affiliation(s)
- Isabella Giacomini
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Federico Gianfanti
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
- Veneto Institute of Molecular Medicine, VIMM, Padova, Italy
| | | | - Genny Orso
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Massimiliano Berretta
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - Tommaso Prayer-Galetti
- Department of Surgery, Oncology and Gastroenterology - Urology, University of Padova, Padova, Italy
| | - Eugenio Ragazzi
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| | - Veronica Cocetta
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
| |
Collapse
|
6
|
Ha NT, Lee CH. Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments. Cells 2020; 9:cells9112352. [PMID: 33113804 PMCID: PMC7693003 DOI: 10.3390/cells9112352] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 10/23/2020] [Accepted: 10/24/2020] [Indexed: 12/14/2022] Open
Abstract
Farnesyl-diphosphate farnesyltransferase 1 (FDFT1, squalene synthase), a membrane-associated enzyme, synthesizes squalene via condensation of two molecules of farnesyl pyrophosphate. Accumulating evidence has noted that FDFT1 plays a critical role in cancer, particularly in metabolic reprogramming, cell proliferation, and invasion. Based on these advances in our knowledge, FDFT1 could be a potential target for cancer treatment. This review focuses on the contribution of FDFT1 to the hallmarks of cancer, and further, we discuss the applicability of FDFT1 as a cancer prognostic marker and target for anticancer therapy.
Collapse
|
7
|
Evaluation of potential inhibitors of squalene synthase based on virtual screening and in vitro studies. Comput Biol Chem 2019; 80:390-397. [DOI: 10.1016/j.compbiolchem.2019.04.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2019] [Revised: 04/01/2019] [Accepted: 04/21/2019] [Indexed: 11/21/2022]
|
8
|
Bi-allelic Mutations in LSS, Encoding Lanosterol Synthase, Cause Autosomal-Recessive Hypotrichosis Simplex. Am J Hum Genet 2018; 103:777-785. [PMID: 30401459 DOI: 10.1016/j.ajhg.2018.09.011] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Accepted: 09/22/2018] [Indexed: 12/25/2022] Open
Abstract
Hypotrichosis simplex (HS) is a rare form of hereditary alopecia characterized by childhood onset of diffuse and progressive scalp and body hair loss. Although research has identified a number of causal genes, genetic etiology in about 50% of HS cases remains unknown. The present report describes the identification via whole-exome sequencing of five different mutations in the gene LSS in three unrelated families with unexplained, potentially autosomal-recessive HS. Affected individuals showed sparse to absent lanugo-like scalp hair, sparse and brittle eyebrows, and sparse eyelashes and body hair. LSS encodes lanosterol synthase (LSS), which is a key enzyme in the cholesterol biosynthetic pathway. This pathway plays an important role in hair follicle biology. After localizing LSS protein expression in the hair shaft and bulb of the hair follicle, the impact of the mutations on keratinocytes was analyzed using immunoblotting and immunofluorescence. Interestingly, wild-type LSS was localized in the endoplasmic reticulum (ER), whereas mutant LSS proteins were localized in part outside of the ER. A plausible hypothesis is that this mislocalization has potential deleterious implications for hair follicle cells. Immunoblotting revealed no differences in the overall level of wild-type and mutant protein. Analyses of blood cholesterol levels revealed no decrease in cholesterol or cholesterol intermediates, thus supporting the previously proposed hypothesis of an alternative cholesterol pathway. The identification of LSS as causal gene for autosomal-recessive HS highlights the importance of the cholesterol pathway in hair follicle biology and may facilitate novel therapeutic approaches for hair loss disorders in general.
Collapse
|
9
|
Hou M, Yan G, Ma X, Luo J, Hou X, Zhou M, Pu C, Han X, Zhang W, Zhang M, Shi J, Li R. Identification of hit compounds for squalene synthase: Three-dimensional quantitative structure-activity relationship pharmacophore modeling, virtual screening, molecular docking, binding free energy calculation, and molecular dynamic simulation. JOURNAL OF CHEMOMETRICS 2017. [DOI: 10.1002/cem.2923] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- M. Hou
- Cancer center, Collaborative Innovation Center for Biotherapy, West China Hospital; Sichuan University; Sichuan 610041 China
| | - G. Yan
- Cancer center, Collaborative Innovation Center for Biotherapy, West China Hospital; Sichuan University; Sichuan 610041 China
| | - X. Ma
- Jiyuan Vocational and technical College; Jiyuan 459000 China
| | - J. Luo
- Cancer center, Collaborative Innovation Center for Biotherapy, West China Hospital; Sichuan University; Sichuan 610041 China
| | - X. Hou
- Cancer center, Collaborative Innovation Center for Biotherapy, West China Hospital; Sichuan University; Sichuan 610041 China
| | - M. Zhou
- Cancer center, Collaborative Innovation Center for Biotherapy, West China Hospital; Sichuan University; Sichuan 610041 China
| | - C. Pu
- Cancer center, Collaborative Innovation Center for Biotherapy, West China Hospital; Sichuan University; Sichuan 610041 China
| | - X. Han
- Cancer center, Collaborative Innovation Center for Biotherapy, West China Hospital; Sichuan University; Sichuan 610041 China
| | - W. Zhang
- Cancer center, Collaborative Innovation Center for Biotherapy, West China Hospital; Sichuan University; Sichuan 610041 China
| | - M. Zhang
- Cancer center, Collaborative Innovation Center for Biotherapy, West China Hospital; Sichuan University; Sichuan 610041 China
| | - J. Shi
- Individualized Medication Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine; University of Electronic Science and Technology of China; Chengdu 610072 Sichuan China
| | - R. Li
- Cancer center, Collaborative Innovation Center for Biotherapy, West China Hospital; Sichuan University; Sichuan 610041 China
| |
Collapse
|
10
|
Shamim D, Laskowski M. Inhibition of Inflammation Mediated Through the Tumor Necrosis Factor α Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease. J Cent Nerv Syst Dis 2017; 9:1179573517722512. [PMID: 28811745 PMCID: PMC5536370 DOI: 10.1177/1179573517722512] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2017] [Accepted: 06/25/2017] [Indexed: 11/17/2022] Open
Abstract
Tumor necrosis factor α (TNF-α) inhibitors have long been used as disease-modifying agents in immune disorders. Recently, research has shown a role of chronic neuroinflammation in the pathophysiology of neurodegenerative diseases such as Alzheimer disease, and interest has been generated in the use of anti-TNF agents and TNF-modulating agents for prevention and treatment. This article extensively reviewed literature on animal studies testing these agents. The results showed a role for direct and indirect TNF-α inhibition through agents such as thalidomide, 3,6-dithiothalidomide, etanercept, infliximab, exendin-4, sodium hydrosulfide, minocycline, imipramine, and atorvastatin. Studies were performed on mice, rats, and monkeys, with induction of neurodegenerative physiology either through the use of chemical agents or through the use of transgenic animals. Most of these agents showed an improvement in cognitive function as tested with the Morris water maze, and immunohistochemical and histopathological staining studies consistently showed better outcomes with these agents. Brains of treated animals showed significant reduction in pro-inflammatory TNF-α and reduced the burden of neurofibrillary tangles, amyloid precursor protein, and β-amyloid plaques. Also, recruitment of microglial cells in the central nervous system was significantly reduced through these drugs. These studies provide a clearer mechanistic understanding of the role of TNF-α modulation in Alzheimer disease. All studies in this review explored the use of these drugs as prophylactic agents to prevent Alzheimer disease through immune modulation of the TNF inflammatory pathway, and their success highlights the need for further research of these drugs as therapeutic agents.
Collapse
Affiliation(s)
- Daniah Shamim
- Saba University School of Medicine, The Bottom, Dutch Caribbean
| | | |
Collapse
|
11
|
Liang Y, Mafuvadze B, Aebi JD, Hyder SM. Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther 2016; 9:3223-32. [PMID: 27313468 PMCID: PMC4892832 DOI: 10.2147/ott.s105725] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Standard treatment for primary prostate cancer includes systemic exposure to chemotherapeutic drugs that target androgen receptor or antihormone therapy (chemical castration); however, drug-resistant cancer cells generally emerge during treatment, limiting the continued use of systemic chemotherapy. Patients are then treated with more toxic standard therapies. Therefore, there is an urgent need for novel and more effective treatments for prostate cancer. The cholesterol biosynthetic pathway is an attractive therapeutic target for treating endocrine-dependent cancers because cholesterol is an essential structural and functional component of cell membranes as well as the metabolic precursor of endogenous steroid hormones. In this study, we have examined the effects of RO 48-8071 (4′-[6-(allylmethylamino)hexyloxy]-4-bromo-2′-fluorobenzophenone fumarate; Roche Pharmaceuticals internal reference: RO0488071) (RO), which is an inhibitor of 2, 3-oxidosqualene cyclase (a key enzyme in the cholesterol biosynthetic pathway), on prostate cancer cells. Exposure of both hormone-dependent and castration-resistant human prostate cancer cells to RO reduced prostate cancer cell viability and induced apoptosis in vitro. RO treatment reduced androgen receptor protein expression in hormone-dependent prostate cancer cells and increased estrogen receptor β (ERβ) protein expression in both hormone-dependent and castration-resistant prostate cancer cell lines. Combining RO with an ERβ agonist increased its ability to reduce castration-resistant prostate cancer cell viability. In addition, RO effectively suppressed the growth of aggressive castration-resistant human prostate cancer cell xenografts in vivo without any signs of toxicity to experimental animals. Importantly, RO did not reduce the viability of normal prostate cells in vitro. Our study is the first to demonstrate that the cholesterol biosynthesis inhibitor RO effectively suppresses growth of human prostate cancer cells. Our findings suggest that cholesterol biosynthesis inhibitors such as RO, when used in combination with commonly used chemotherapeutic drugs or ERβ specific ligands, could represent a novel therapeutic approach to prevent the growth of prostate cancer tumors.
Collapse
Affiliation(s)
- Yayun Liang
- Dalton Cardiovascular Research Center and Department of Biomedical Sciences, University of Missouri-Columbia, Columbia, MO, USA
| | - Benford Mafuvadze
- Dalton Cardiovascular Research Center and Department of Biomedical Sciences, University of Missouri-Columbia, Columbia, MO, USA
| | - Johannes D Aebi
- Medicinal Chemistry, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F Hoffmann-La Roche Ltd., Basel, Switzerland
| | - Salman M Hyder
- Dalton Cardiovascular Research Center and Department of Biomedical Sciences, University of Missouri-Columbia, Columbia, MO, USA
| |
Collapse
|
12
|
Warchol I, Gora M, Wysocka-Kapcinska M, Komaszylo J, Swiezewska E, Sojka M, Danikiewicz W, Plochocka D, Maciejak A, Tulacz D, Leszczynska A, Kapur S, Burzynska B. Genetic engineering and molecular characterization of yeast strain expressing hybrid human-yeast squalene synthase as a tool for anti-cholesterol drug assessment. J Appl Microbiol 2016; 120:877-88. [PMID: 26757023 DOI: 10.1111/jam.13053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Revised: 10/27/2015] [Accepted: 01/05/2016] [Indexed: 11/29/2022]
Abstract
AIMS The main objective of the study is molecular and biological characterization of the human-yeast hybrid squalene synthase (SQS), as a promising target for treatment of hypercholesterolaemia. METHODS AND RESULTS The human-yeast hybrid SQS, with 67% amino acids, including the catalytic site derived from human enzyme, was expressed in Saccharomyces cerevisiae strain deleted of its own SQS gene. The constructed strain has a decreased level of sterols compared to the control strain. The mevalonate pathway and sterol biosynthesis genes are induced and the level of triacylglycerols is increased. Treatment of the strain with rosuvastatin or zaragozic acid, two mevalonate pathway inhibitors, decreased the amounts of squalene, lanosterol and ergosterol, and up-regulated expression of several genes encoding enzymes responsible for biosynthesis of ergosterol precursors. Conversely, expression of the majority genes implicated in the biosynthesis of other mevalonate pathway end products, ubiquinone and dolichol, was down-regulated. CONCLUSIONS The S. cerevisiae strain constructed in this study enables to investigate the physiological and molecular effects of inhibitors on cell functioning. SIGNIFICANCE AND IMPACT OF THE STUDY The yeast strain expressing hybrid SQS with the catalytic core of human enzyme is a convenient tool for efficient screening for novel inhibitors of cholesterol-lowering properties.
Collapse
Affiliation(s)
- I Warchol
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| | - M Gora
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| | - M Wysocka-Kapcinska
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| | - J Komaszylo
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| | - E Swiezewska
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| | - M Sojka
- Institute of Organic Chemistry, Polish Academy of Sciences, Warsaw, Poland
| | - W Danikiewicz
- Institute of Organic Chemistry, Polish Academy of Sciences, Warsaw, Poland
| | - D Plochocka
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| | - A Maciejak
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| | - D Tulacz
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| | - A Leszczynska
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| | - S Kapur
- Department of Biological Science, Birla Institute of Technology & Science (BITS), Hyderabad, India
| | - B Burzynska
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| |
Collapse
|
13
|
Shiuan D, Lin HK, Chen YH, Chang DK, Huang KJ, Farh L. Exploration of Peptide Inhibitors of Human Squalene Synthase through Molecular Modeling and Phage Display Technique. Appl Biochem Biotechnol 2015; 178:312-23. [PMID: 26438313 DOI: 10.1007/s12010-015-1873-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Accepted: 09/24/2015] [Indexed: 11/29/2022]
Abstract
Many studies have demonstrated the role of elevated levels of serum cholesterol in the pathogenesis of atherosclerosis and coronary heart disease. Various drugs targeting the key enzymes involved in the cholesterol biosynthesis pathway have been investigated for the treatment of hypercholesterolemia. Human squalene synthase has been one of the most important targets for therapeutic intervention. In the present study, we used the recombinant human squalene synthase as the lure for screening the peptide inhibitors from phage-displayed random peptide library. The tightly bound phages and their derived peptides were further evaluated based on their potential binding capabilities, molecular modeling characteristics and predicted absorption, distribution, metabolism, excretion, toxicity (ADMET) properties. Several hexa-peptides and tetra-peptides were finally synthesized to assay their inhibitory effects toward the recombinant human squalene synthase. The results demonstrated that the hexa-peptide FTACNW and tetra-peptide VACL can inhibit human squalene synthase effectively (with IC50 values near 100 μM) and may have potential to develop further as future hypocholesterolemia agents.
Collapse
Affiliation(s)
- David Shiuan
- Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien, Taiwan, 974, Republic of China.
| | - Hwan-Kang Lin
- Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien, Taiwan, 974, Republic of China
| | - Yue-Hao Chen
- Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien, Taiwan, 974, Republic of China
| | - Ding-Kwo Chang
- Institute of Chemistry, Academia Sinica, Taipei, Taiwan, 115, Republic of China
| | - Kao-Jean Huang
- Development Center for Biotechnology, Taipei, Taiwan, 221, Republic of China
| | - Lynn Farh
- Department of Applied Chemistry, National Pingtung University, Pingtung, Taiwan, 900, Republic of China
| |
Collapse
|
14
|
Trenin AS. [Microbial metabolites that inhibit sterol biosynthesis, their chemical diversity and characteristics of mode of action]. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2015; 39:633-57. [PMID: 25696927 DOI: 10.1134/s1068162013060095] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Inhibitors of sterol biosynthesis (ISB) are widespread in nature and characterized by appreciable diversity both in their chemical structure and mode of action. Many of these inhibitors express noticeable biological activity and approved themselves in development of various pharmaceuticals. In this review there is a detailed description of biologically active microbial metabolites with revealed chemical structure that have ability to inhibit sterol biosynthesis. Inhibitors of mevalonate pathway in fungous and mammalian cells, exhibiting hypolipidemic or antifungal activity, as well as inhibitors of alternative non-mevalonate (pyruvate gliceraldehyde phosphate) isoprenoid pathway, which are promising in the development of affective antimicrobial or antiparasitic drugs, are under consideration in this review. Chemical formulas of the main natural inhibitors and their semi-synthetic derivatives are represented. Mechanism of their action at cellular and biochemical level is discussed. Special attention is given to inhibitors of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase (group of lovastatin) and inhibitors of acyl-CoA-cholesterol-acyl transferase (ACAT) that possess hypolipidemic activity and could be affective in the treatment of atherosclerosis. In case of inhibitors of late stages of sterol biosynthesis (after squalene formation) special attention is paid to compounds possessing evident antifungal and antitumoral activity. Explanation of mechanism of anticancer and antiviral action of microbial ISB, as well as the description of their ability to induce apoptosis is given.
Collapse
|
15
|
The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. Sci Rep 2015; 5:9054. [PMID: 25761781 PMCID: PMC4357009 DOI: 10.1038/srep09054] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Accepted: 02/16/2015] [Indexed: 12/13/2022] Open
Abstract
Aberrant cholesterol homeostasis and biosynthesis has been observed in different tumour types. This paper investigates the role of the post-squalenic enzyme of cholesterol biosynthesis, oxidosqualene cyclase (OSC), in regulating tumour angiogenesis and metastasis dissemination in mouse models of cancer. We showed that Ro 48-8071, a selective inhibitor of OSC, reduced vascular density and increased pericyte coverage, with a consequent inhibition of tumour growth in a spontaneous mouse model of pancreatic tumour (RIP-Tag2) and two metastatic mouse models of human colon carcinoma (HCT116) and pancreatic adenocarcinoma (HPAF-II). Remarkably, the inhibition of OSC hampered metastasis formation in HCT116 and HPAF-II models. Ro 48-8071 induced tumour vessel normalization and enhanced the anti-tumoral and anti-metastatic effects of 5-fluorouracil (5-FU) in HCT116 mice. Ro 48-8071 exerted a strong anti-angiogenic activity by impairing endothelial cell adhesion and migration, and by blocking vessel formation in angiogenesis assays. OSC inhibition specifically interfered with the PI3K pathway. According to in vitro results, Ro 48-8071 specifically inhibited Akt phosphorylation in both cancer cells and tumour vasculature in all treated models. Thus, our results unveil a crucial role of OSC in the regulation of cancer progression and tumour angiogenesis, and indicate Ro 48-8071 as a potential novel anti-angiogenic and anti-metastatic drug.
Collapse
|
16
|
Abderrazak A, Couchie D, Mahmood DFD, Elhage R, Vindis C, Laffargue M, Matéo V, Büchele B, Ayala MR, El Gaafary M, Syrovets T, Slimane MN, Friguet B, Fulop T, Simmet T, El Hadri K, Rouis M. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Circulation 2015; 131:1061-70. [PMID: 25613820 DOI: 10.1161/circulationaha.114.013730] [Citation(s) in RCA: 136] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND This study was designed to evaluate the effect of arglabin on the NLRP3 inflammasome inhibition and atherosclerotic lesion in ApoE2Ki mice fed a high-fat Western-type diet. METHODS AND RESULTS Arglabin was purified, and its chemical identity was confirmed by mass spectrometry. It inhibited, in a concentration-dependent manner, interleukin (IL)-1β and IL-18, but not IL-6 and IL-12, production in lipopolysaccharide and cholesterol crystal-activated cultured mouse peritoneal macrophages, with a maximum effect at ≈50 nmol/L and EC50 values for both cytokines of ≈ 10 nmol/L. Lipopolysaccharide and cholesterol crystals did not induce IL-1β and IL-18 production in Nlrp3(-/-) macrophages. In addition, arglabin activated autophagy as evidenced by the increase in LC3-II protein. Intraperitoneal injection of arglabin (2.5 ng/g body weight twice daily for 13 weeks) into female ApoE2.Ki mice fed a high-fat diet resulted in a decreased IL-1β plasma level compared with vehicle-treated mice (5.2±1.0 versus 11.7±1.1 pg/mL). Surprisingly, arglabin also reduced plasma levels of total cholesterol and triglycerides to 41% and 42%, respectively. Moreover, arglabin oriented the proinflammatory M1 macrophages into the anti-inflammatory M2 phenotype in spleen and arterial lesions. Finally, arglabin treatment markedly reduced the median lesion areas in the sinus and whole aorta to 54% (P=0.02) and 41% (P=0.02), respectively. CONCLUSIONS Arglabin reduces inflammation and plasma lipids, increases autophagy, and orients tissue macrophages into an anti-inflammatory phenotype in ApoE2.Ki mice fed a high-fat diet. Consequently, a marked reduction in atherosclerotic lesions was observed. Thus, arglabin may represent a promising new drug to treat inflammation and atherosclerosis.
Collapse
Affiliation(s)
- Amna Abderrazak
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Dominique Couchie
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Dler Faieeq Darweesh Mahmood
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Rima Elhage
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Cécile Vindis
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Muriel Laffargue
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Véronique Matéo
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Berthold Büchele
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Monica Rubio Ayala
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Menna El Gaafary
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Tatiana Syrovets
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Mohamed-Naceur Slimane
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Bertrand Friguet
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Tamas Fulop
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Thomas Simmet
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Khadija El Hadri
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.)
| | - Mustapha Rouis
- From Sorbonne Universités, UPMC Université Paris 06, Biological Adaptation and Ageing-IBPS, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); CNRS-UMR 8256, Paris, France (A.A., D.C., D.F.D.M., R.E.H., F.B., K.E.H., M.R.); Inserm U1164, Paris, France (A.A., D.C., D.F.D.M., R.E.H., B.F., K.E.H., M.R.); INSERM-UPS UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France (C.V., M.L.); Centre de Recherche d'Immunologie et Maladies Infectieuses, CIMI-Paris UPMC UMRS CR7, INSERM U-1135, CNRS ERL 8255, Hôpital Pitié-Salpêtrière, Paris, France (V.M.); Ulm University, Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm, Germany (B.B., M.R.A., M.E.G., T.S., T.S.); Biochemistry Laboratory, Faculty of Medicine, TN-Monastir, Tunisia (M.-N.S.); and Centre de Recherche sur le Vieillissement, Service Gériatrique, Département de Médecine, Université de Sherbrooke, Sherbrooke, QC, Canada (T.F.).
| |
Collapse
|
17
|
Liang Y, Besch-Williford C, Aebi JD, Mafuvadze B, Cook MT, Zou X, Hyder SM. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Res Treat 2014; 146:51-62. [PMID: 24878988 PMCID: PMC11121502 DOI: 10.1007/s10549-014-2996-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2014] [Accepted: 05/08/2014] [Indexed: 02/06/2023]
Abstract
In most human breast cancers, tumor cell proliferation is estrogen dependent. Although hormone-responsive tumors initially respond to anti-estrogen therapies, most of them eventually develop resistance. Our goal was to identify alternative targets that might be regulated to control breast cancer progression. Sulforhodamine B assay was used to measure the viability of cultured human breast cancer cell lines exposed to various inhibitors. Protein expression in whole-cell extracts was determined by Western blotting. BT-474 tumor xenografts in nude mice were used for in vivo studies of tumor progression. RO 48-8071 ([4'-[6-(Allylmethylamino)hexyloxy]-4-bromo-2'-fluorobenzophenone fumarate]; RO), a small-molecule inhibitor of oxidosqualene cyclase (OSC, a key enzyme in cholesterol biosynthesis), potently reduced breast cancer cell viability. In vitro exposure of estrogen receptor (ER)-positive human breast cancer cells to pharmacological levels of RO or a dose close to the IC50 for OSC (nM) reduced cell viability. Administration of RO to mice with BT-474 tumor xenografts prevented tumor growth, with no apparent toxicity. RO degraded ERα while concomitantly inducing the anti-proliferative protein ERβ. Two other cholesterol-lowering drugs, Fluvastatin and Simvastatin, were less effective in reducing breast cancer cell viability and were found not to induce ERβ. ERβ inhibition or knockdown prevented RO-dependent loss of cell viability. Importantly, RO had no effect on the viability of normal human mammary cells. RO is a potent inhibitor of hormone-dependent human breast cancer cell proliferation. The anti-tumor properties of RO appear to be in part due to an off-target effect that increases the ratio of ERβ/ERα in breast cancer cells.
Collapse
Affiliation(s)
- Yayun Liang
- Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, 65211, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
France M, Schofield J, Kwok S, Soran H. Treatment of homozygous familial hypercholesterolemia. ACTA ACUST UNITED AC 2014. [DOI: 10.2217/clp.13.79] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
19
|
Furubayashi M, Li L, Katabami A, Saito K, Umeno D. Construction of carotenoid biosynthetic pathways using squalene synthase. FEBS Lett 2013; 588:436-42. [PMID: 24333579 DOI: 10.1016/j.febslet.2013.12.003] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2013] [Revised: 11/28/2013] [Accepted: 12/03/2013] [Indexed: 10/25/2022]
Abstract
The first committed steps of steroid/hopanoid pathways involve squalene synthase (SQS). Here, we report the Escherichia coli production of diaponeurosporene and diapolycopene, yellow C30 carotenoid pigments, by expressing human SQS and Staphylococcus aureus dehydrosqualene (C30 carotenoid) desaturase (CrtN). We suggest that the carotenoid pigments are synthesized mainly via the desaturation of squalene rather than the direct synthesis of dehydrosqualene through the non-reductive condensation of prenyl diphosphate precursors, indicating the possible existence of a "squalene route" and a "lycopersene route" for C30 and C40 carotenoids, respectively. Additionally, this finding yields a new method of colorimetric screening for the cellular activity of squalene synthases, which are major targets for cholesterol-lowering drugs.
Collapse
Affiliation(s)
- Maiko Furubayashi
- Department of Applied Chemistry and Biotechnology, Chiba University, 1-33, Yayoi-cho, Inage, Chiba 263-8522, Japan
| | - Ling Li
- Department of Applied Chemistry and Biotechnology, Chiba University, 1-33, Yayoi-cho, Inage, Chiba 263-8522, Japan
| | - Akinori Katabami
- Department of Applied Chemistry and Biotechnology, Chiba University, 1-33, Yayoi-cho, Inage, Chiba 263-8522, Japan
| | - Kyoichi Saito
- Department of Applied Chemistry and Biotechnology, Chiba University, 1-33, Yayoi-cho, Inage, Chiba 263-8522, Japan
| | - Daisuke Umeno
- Department of Applied Chemistry and Biotechnology, Chiba University, 1-33, Yayoi-cho, Inage, Chiba 263-8522, Japan; Precursory Research for Embryonic Science and Technology (PRESTO), Japan Science and Technology Agency (JST), 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan.
| |
Collapse
|
20
|
Ladopoulou E, Matralis AN, Kourounakis AP. New Multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine Derivatives with Antioxidant, Antihyperlipidemic, and Antidiabetic Action. J Med Chem 2013; 56:3330-8. [DOI: 10.1021/jm400101e] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Eleni Ladopoulou
- Department
of Medicinal Chemistry, School of Pharmacy, University of Athens, 15771 Athens, Greece
| | - Alexios N. Matralis
- Department
of Medicinal Chemistry, School of Pharmacy, University of Athens, 15771 Athens, Greece
| | - Angeliki P. Kourounakis
- Department
of Medicinal Chemistry, School of Pharmacy, University of Athens, 15771 Athens, Greece
| |
Collapse
|
21
|
Zhang YY, Fan YC, Wang M, Wang D, Li XH. Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease. Clin Interv Aging 2013; 8:103-10. [PMID: 23386786 PMCID: PMC3563315 DOI: 10.2147/cia.s40405] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background and aim Amyloid-beta (Aβ) peptide is reported to initiate flexible inflammation in the hippocampus of the human brain in Alzheimer’s disease (AD). The present study aimed to investigate the possible effects of atorvastatin on the production of inflammation cytokines in the hippocampus and the potential impacts on behavioral ability, in an AD model. Methods We firstly established AD rat models using intracerebroventricular injection of Aβ1-42. A Morris water maze was also performed to determine the spatial learning and memory ability in the AD models. Intracellular staining of interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha was determined using immunohistochemical staining at 6 hours and day 7 after the injection of Aβ. Results The escape latency of the atorvastatin-treated AD group (5 mg/kg/d) was significantly shorter than that of AD group on day 3 (41 ± 1.05 seconds versus 47 ± 1.05 seconds, P < 0.01) and day 4 (34 ± 1.25 seconds versus 43 ± 1.01 seconds, P < 0.01) after the beginning of the training. Furthermore, the atorvastatin-treated AD group displayed a significant higher mean number of annulus crossings than did the AD group (2.9 ± 0.5 versus 2.4 ± 0.9, P < 0.05). Fewer injured nerve cells and proliferated glial cells were also demonstrated in the atorvastatin-treated AD group than in the AD group. Of great importance, we demonstrated that IL-1β, IL-6, and tumor necrosis factor alpha were significantly decreased in the atorvastatin-treated AD group than that in the AD group. Conclusion Atorvastatin might attenuate the damage of nerve cells and improve learning and memory ability by inhibiting inflammatory response in the progression of AD.
Collapse
Affiliation(s)
- Yuan-Yuan Zhang
- Department of Neurology, Jinan Central Hospital affiliated to Shandong University, Jinan, People's Republic of China
| | | | | | | | | |
Collapse
|
22
|
Efficient reduction of serum cholesterol by combining a liver-targeted gene delivery system with chemically modified apolipoprotein B siRNA. J Control Release 2012; 163:119-24. [DOI: 10.1016/j.jconrel.2012.08.030] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2012] [Revised: 08/24/2012] [Accepted: 08/29/2012] [Indexed: 12/19/2022]
|
23
|
Trapani L, Segatto M, Pallottini V. Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic "power station". World J Hepatol 2012; 4:184-90. [PMID: 22761969 PMCID: PMC3388116 DOI: 10.4254/wjh.v4.i6.184] [Citation(s) in RCA: 117] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2011] [Revised: 06/21/2012] [Accepted: 06/25/2012] [Indexed: 02/06/2023] Open
Abstract
Cholesterol plays several structural and metabolic roles that are vital for human biology. It spreads along the entire plasma membrane of the cell, modulating fluidity and concentrating in specialized sphingolipid-rich domains called rafts and caveolae. Cholesterol is also a substrate for steroid hormones. However, too much cholesterol can lead to pathological pictures such as atherosclerosis, which is a consequence of the accumulation of cholesterol into the cells of the artery wall. The liver is considered to be the metabolic power station of mammalians, where cholesterol homeostasis relies on an intricate network of cellular processes whose deregulations can lead to several life-threatening pathologies, such as familial and age-related hypercholesterolemia. Cholesterol homeostasis maintenance is carried out by: biosynthesis, via 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity; uptake, through low density lipoprotein receptors (LDLr); lipoprotein release in the blood; storage by esterification; and degradation and conversion into bile acids. Both HMGR and LDLr are transcribed as a function of cellular sterol amount by a family of transcription factors called sterol regulatory element binding proteins that are responsible for the maintenance of cholesterol homeostasis through an intricate mechanism of regulation. Cholesterol obtained by hepatic de novo synthesis can be esterified and incorporated into apolipoprotein B-100-containing very low density lipoproteins, which are then secreted into the bloodstream for transport to peripheral tissues. Moreover, dietary cholesterol is transferred from the intestine to the liver by high density lipoproteins (HDLs); all HDL particles are internalized in the liver, interacting with the hepatic scavenger receptor (SR-B1). Here we provide an updated overview of liver cholesterol metabolism regulation and deregulation and the causes of cholesterol metabolism-related diseases. Moreover, current pharmacological treatment and novel hypocholesterolemic strategies will also be introduced.
Collapse
Affiliation(s)
- Laura Trapani
- Laura Trapani, Marco Segatto, Valentina Pallottini, Department of Biology, University Roma Tre, Viale Marconi 446, 00146 Rome, Italy
| | | | | |
Collapse
|
24
|
Welti M. Regulation of dolichol-linked glycosylation. Glycoconj J 2012; 30:51-6. [DOI: 10.1007/s10719-012-9417-y] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2012] [Revised: 06/06/2012] [Accepted: 06/11/2012] [Indexed: 11/28/2022]
|
25
|
Tanos R, Patel RD, Murray IA, Smith PB, Perdew GH, Perdew GH. Aryl hydrocarbon receptor regulates the cholesterol biosynthetic pathway in a dioxin response element-independent manner. Hepatology 2012; 55:1994-2004. [PMID: 22234961 PMCID: PMC3340481 DOI: 10.1002/hep.25571] [Citation(s) in RCA: 112] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]
Abstract
UNLABELLED The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor. Activation of AhR mediates the expression of target genes (e.g., CYP1A1) by binding to dioxin response element (DRE) sequences in their promoter region. To understand the multiple mechanisms of AhR-mediated gene regulation, a microarray analysis on liver isolated from ligand-treated transgenic mice expressing a wild-type (WT) Ahr or a DRE-binding mutant Ahr (A78D) on an ahr-null background was performed. Results revealed that AhR DRE binding is not required for the suppression of genes involved in cholesterol synthesis. Quantitative reverse-transcription polymerase chain reaction performed on both mouse liver and primary human hepatocyte RNA demonstrated a coordinated repression of genes involved in cholesterol biosynthesis, namely, HMGCR, FDFT1, SQLE, and LSS after receptor activation. An additional transgenic mouse line was established expressing a liver-specific Ahr-A78D on a Cre(Alb)/Ahr(flox/flox) background. These mice displayed a similar repression of cholesterol biosynthetic genes, compared to Ahr(flox/flox) mice, further indicating that the observed modulation is AhR specific and occurs in a DRE-independent manner. Elevated hepatic transcriptional levels of the genes of interest were noted in congenic C57BL/6J-Ah(d) allele mice, when compared to the WT C57BL/6J mice, which carry the Ah(b) allele. Down-regulation of AhR nuclear translocator levels using short interfering RNA in a human cell line revealed no effect on the expression of cholesterol biosynthetic genes. Finally, cholesterol secretion was shown to be significantly decreased in human cells after AhR activation. CONCLUSION These data firmly establish an endogenous role for AhR as a regulator of the cholesterol biosynthesis pathway independent of its DRE-binding ability, and suggest that AhR may be a previously unrecognized therapeutic target.
Collapse
Affiliation(s)
| | | | | | | | - Gary H. Perdew
- To whom correspondence should be addressed. Telephone: (814) 865-0400. Fax: 814-863-1696.
| | | |
Collapse
|
26
|
Liu CI, Jeng WY, Chang WJ, Ko TP, Wang AHJ. Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase. J Biol Chem 2012; 287:18750-7. [PMID: 22474324 DOI: 10.1074/jbc.m112.351254] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Zaragozic acids (ZAs) belong to a family of fungal metabolites with nanomolar inhibitory activity toward squalene synthase (SQS). The enzyme catalyzes the committed step of sterol synthesis and has attracted attention as a potential target for antilipogenic and antiinfective therapies. Here, we have determined the structure of ZA-A complexed with human SQS. ZA-A binding induces a local conformational change in the substrate binding site, and its C-6 acyl group also extends over to the cofactor binding cavity. In addition, ZA-A effectively inhibits a homologous bacterial enzyme, dehydrosqualene synthase (CrtM), which synthesizes the precursor of staphyloxanthin in Staphylococcus aureus to cope with oxidative stress. Size reduction at Tyr(248) in CrtM further increases the ZA-A binding affinity, and it reveals a similar overall inhibitor binding mode to that of human SQS/ZA-A except for the C-6 acyl group. These structures pave the way for further improving selectivity and development of a new generation of anticholesterolemic and antimicrobial inhibitors.
Collapse
Affiliation(s)
- Chia-I Liu
- Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan
| | | | | | | | | |
Collapse
|
27
|
Wallace IM, Urbanus ML, Luciani GM, Burns AR, Han MKL, Wang H, Arora K, Heisler LE, Proctor M, St Onge RP, Roemer T, Roy PJ, Cummins CL, Bader GD, Nislow C, Giaever G. Compound prioritization methods increase rates of chemical probe discovery in model organisms. ACTA ACUST UNITED AC 2012; 18:1273-83. [PMID: 22035796 DOI: 10.1016/j.chembiol.2011.07.018] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2010] [Revised: 06/29/2011] [Accepted: 07/15/2011] [Indexed: 11/30/2022]
Abstract
Preselection of compounds that are more likely to induce a phenotype can increase the efficiency and reduce the costs for model organism screening. To identify such molecules, we screened ~81,000 compounds in Saccharomyces cerevisiae and identified ~7500 that inhibit cell growth. Screening these growth-inhibitory molecules across a diverse panel of model organisms resulted in an increased phenotypic hit-rate. These data were used to build a model to predict compounds that inhibit yeast growth. Empirical and in silico application of the model enriched the discovery of bioactive compounds in diverse model organisms. To demonstrate the potential of these molecules as lead chemical probes, we used chemogenomic profiling in yeast and identified specific inhibitors of lanosterol synthase and of stearoyl-CoA 9-desaturase. As community resources, the ~7500 growth-inhibitory molecules have been made commercially available and the computational model and filter used are provided.
Collapse
Affiliation(s)
- Iain M Wallace
- Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario M5S 3E1, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Seyhan AA, Varadarajan U, Choe S, Liu W, Ryan TE. A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. MOLECULAR BIOSYSTEMS 2012; 8:1553-70. [PMID: 22446932 DOI: 10.1039/c2mb05512k] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Neratinib (HKI-272) is a small molecule tyrosine kinase inhibitor of the ErbB receptor family currently in Phase III clinical trials. Despite its efficacy, the mechanism of potential cellular resistance to neratinib and genes involved with it remains unknown. We have used a pool-based lentiviral genome-wide functional RNAi screen combined with a lethal dose of neratinib to discover chemoresistant interactions with neratinib. Our screen has identified a collection of genes whose inhibition by RNAi led to neratinib resistance including genes involved in oncogenesis (e.g. RAB33A, RAB6A and BCL2L14), transcription factors (e.g. FOXP4, TFEC, ZNF), cellular ion transport (e.g. CLIC3, TRAPPC2P1, P2RX2), protein ubiquitination (e.g. UBL5), cell cycle (e.g. CCNF), and genes known to interact with breast cancer-associated genes (e.g. CCNF, FOXP4, TFEC, several ZNF factors, GNA13, IGFBP1, PMEPA1, SOX5, RAB33A, RAB6A, FXR1, DDO, TFEC, OLFM2). The identification of novel mediators of cellular resistance to neratinib could lead to the identification of new or neoadjuvant drug targets. Their use as patient or treatment selection biomarkers could make the application of anti-ErbB therapeutics more clinically effective.
Collapse
Affiliation(s)
- Attila A Seyhan
- Systems Biology, Global Biotherapeutics, Pfizer Inc., 200 Cambridgepark Drive, Cambridge, MA 02140, USA.
| | | | | | | | | |
Collapse
|
29
|
Trapani L, Segatto M, Ascenzi P, Pallottini V. Potential role of nonstatin cholesterol lowering agents. IUBMB Life 2011; 63:964-71. [PMID: 21990243 DOI: 10.1002/iub.522] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2011] [Accepted: 05/27/2011] [Indexed: 01/24/2023]
Abstract
Although statins, 3β-hydroxy-3β-methylglutaryl coenzyme A reductase (HMGR) inhibitors, have revolutionized the management of cardiovascular diseases by lowering serum low density lipoproteins, many patients suffer from their side effects. Whether the statin side effects are related to their intrinsic toxicity or to the decrease of HMGR main isoprenoid end products, which are essential compounds for cell viability, is still debated. In addition to HMGR, the key and rate limiting step of cholesterol synthesis, many enzymes are involved in this multi-step pathway whose inhibition could be taken into account for a "nonstatin approach" in the management of hypercholesterolemia. In particular, due to their unique position downstream from HMGR, the inhibition of squalene synthase, farnesyl diphosphate farnesyltransferase (FDFT1), squalene epoxidase (SQLE), and oxidosqualene cyclase:lanosterol synthase (OSC) should decrease plasma levels of cholesterol without affecting ubiquinone, dolichol, and isoprenoid metabolism. Thus, although FDFT1, SQLE and OSC are little studied, they should be considered as perspective targets for the development of novel drugs against hypercholesterolemia. Here, structure-function relationships of FDFT1, SQLE, and OSC are reviewed highlighting the advantages that the downstream inhibition of HMGR could provide when compared to the statin-based therapy.
Collapse
Affiliation(s)
- Laura Trapani
- Department of Biology, University Roma Tre, Viale Guglielmo Marconi 446, Roma, Italy
| | | | | | | |
Collapse
|
30
|
Matralis AN, Katselou MG, Nikitakis A, Kourounakis AP. Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents. J Med Chem 2011; 54:5583-91. [PMID: 21702499 DOI: 10.1021/jm200763k] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Atherosclerosis is a multifactorial disease with several mechanisms participating in its manifestation. To address this disorder, we applied a strategy involving the design of a single chemical compound able to simultaneously modulate more than one target. We hereby present the development of novel benzoxazine and benzothiazine derivatives that significantly inhibit in vitro microsomal lipid peroxidation and LDL oxidation as well as squalene synthase activity (IC(50) of 5-16 μM). Further, these compounds show antidyslipidemic and antioxidant properties in vivo, decreasing total cholesterol, LDL, triglyceride, and MDA levels of hyperlipidemic rats by 26-74%. Finally, by determination of their in vivo concentration (up to 24 h) in target tissues (blood/liver), it is shown that compounds reach their targets in the low micromolar range. The new compounds seem to be interesting multifunctional molecules for the development of a new pharmacophore for disease-modifying agents useful in the treatment of atherosclerosis.
Collapse
Affiliation(s)
- Alexios N Matralis
- Department of Medicinal Chemistry, School of Pharmacy, University of Athens, Athens, Greece
| | | | | | | |
Collapse
|
31
|
Koohang A, Bailey JL, Coates RM, Erickson HK, Owen D, Poulter CD. Enantioselective inhibition of squalene synthase by aziridine analogues of presqualene diphosphate. J Org Chem 2010; 75:4769-77. [PMID: 20545375 DOI: 10.1021/jo100718z] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Squalene synthase catalyzes the conversion of two molecules of (E,E)-farnesyl diphosphate to squalene via the cyclopropylcarbinyl intermediate, presqualene diphosphate (PSPP). Since this novel reaction constitutes the first committed step in sterol biosynthesis, there has been considerable interest and research on the stereochemistry and mechanism of the process and in the design of selective inhibitors of the enzyme. This paper reports the synthesis and characterization of five racemic and two enantiopure aziridine analogues of PSPP and the evaluation of their potencies as inhibitors of recombinant yeast squalene synthase. The key aziridine-2-methanol intermediates (6-OH, 7-OH, and 8-OH) were obtained by N-alkylations or by an N-acylation-reduction sequence of (+/-)-, (2R,3S)-, and (2S,3R)-2,3-aziridinofarnesol (9-OH) protected as tert-butyldimethylsilyl ethers. S(N)2 displacements of the corresponding methanesulfonates with pyrophosphate and methanediphosphonate anions afforded aziridine 2-methyl diphosphates and methanediphosphonates bearing N-undecyl, N-bishomogeranyl, and N-(alpha-methylene)bishomogeranyl substituents as mimics for the 2,6,10-trimethylundeca-2,5,9-trienyl side chain of PSPP. The 2R,3S diphosphate enantiomer bearing the N-bishomogeranyl substituent corresponding in absolute stereochemistry to PSPP proved to be the most potent inhibitor (IC(50) 1.17 +/- 0.08 muM in the presence of inorganic pyrophosphate), a value 4-fold less than that of its 2S,3R stereoisomer. The other aziridine analogues bearing the N-(alpha-methylene)bishomogeranyl and N-undecyl substituents, and the related methanediphosphonates, exhibited lower affinities for recombinant squalene synthase.
Collapse
Affiliation(s)
- Ali Koohang
- Department of Chemistry, University of Illinois, 600 South Mathews Avenue, Urbana, Illinois 61801, USA
| | | | | | | | | | | |
Collapse
|
32
|
Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115:55-68. [PMID: 19900395 DOI: 10.1016/j.actatropica.2009.10.023] [Citation(s) in RCA: 323] [Impact Index Per Article: 23.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2009] [Revised: 10/22/2009] [Accepted: 10/26/2009] [Indexed: 01/31/2023]
Abstract
A critical review of the development of specific chemotherapeutic approaches for the management of American Trypanosomiasis or Chagas disease is presented, including controversies on the pathogenesis of the disease, the initial efforts that led to the development of currently available drugs (nifurtimox and benznidazole), limitations of these therapies and novel approaches for the development of anti-Trypanosoma cruzi drugs, based on our growing understanding of the biology of this parasite. Among the later, the most promising approaches are ergosterol biosynthesis inhibitors such as posaconazole and ravuconazole, poised to enter clinical trials for chronic Chagas disease in the short term; inhibitors of cruzipain, the main cysteine protease of T. cruzi, essential for its survival and proliferation in vitro and in vivo; bisphosphonates, metabolic stable pyrophosphate analogs that have trypanocidal activity through the inhibition of the parasite's farnesyl-pyrophosphate synthase or hexokinase; inhibitors of trypanothione synthesis and redox metabolism and inhibitors of hypoxanthine-guanine phosphoribosyl-transferase, an essential enzyme for purine salvage in T. cruzi and related organisms. Finally, the economic and political challenges faced by development of drugs for the treatment of neglected tropical diseases, which afflict almost exclusively poor populations in developing countries, are analyzed and recent potential solutions for this conundrum are discussed.
Collapse
|
33
|
Nikitakis A, Kourounakis AP. QSAR of substituted morpholines with antioxidant and squalene synthase inhibitory activity. Med Chem Res 2010. [DOI: 10.1007/s00044-010-9351-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
34
|
Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 2010; 104 Suppl 1:311-8. [PMID: 19753490 DOI: 10.1590/s0074-02762009000900041] [Citation(s) in RCA: 146] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2009] [Accepted: 05/18/2009] [Indexed: 12/13/2022] Open
Abstract
This article presents an overview of the currently available drugs nifurtimox (NFX) and benznidazole (BZN) used against Trypanosoma cruzi, the aetiological agent of Chagas disease; herein we discuss their limitations along with potential alternatives with a focus on ergosterol biosynthesis inhibitors (EBI). These compounds are currently the most advanced candidates for new anti-T. cruzi agents given that they block de novo production of 24-alkyl-sterols, which are essential for parasite survival and cannot be replaced by a host's own cholesterol. Among these compounds, new triazole derivatives that inhibit the parasite's C14alpha sterol demethylase are the most promising, as they have been shown to have curative activity in murine models of acute and chronic Chagas disease and are active against NFX and BZN-resistant T. cruzi strains; among this class of compounds, posaconazole (Schering-Plough Research Institute) and ravuconazole (Eisai Company) are poised for clinical trials in Chagas disease patients in the short term. Other T. cruzi-specific EBI, with in vitro and in vivo potency, include squalene synthase, lanosterol synthase and squalene epoxidase-inhibitors as well as compounds with dual mechanisms of action (ergosterol biosynthesis inhibition and free radical generation), but they are less advanced in their development process. The main putative advantages of EBI over currently available therapies include their higher potency and selectivity in both acute and chronic infections, activity against NFX and BZN-resistant T. cruzi strains, and much better tolerability and safety profiles. Limitations may include complexity and cost of manufacture of the new compounds. As for any new drug, such compounds will require extensive clinical testing before being introduced for clinical use, and the complexity of such studies, particularly in chronic patients, will be compounded by the current limitations in the verification of true parasitological cures for T. cruzi infections.
Collapse
Affiliation(s)
- Julio A Urbina
- Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela.
| |
Collapse
|
35
|
Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. Cardiol Rev 2009; 17:70-6. [PMID: 19367148 DOI: 10.1097/crd.0b013e3181885905] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Hypercholesterolemia is a major risk factor for the development of atherosclerotic vascular diseases. The most popular agents for cholesterol reduction are the statin drugs, which are competitive inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the primary rate-limiting enzyme in the hepatic biosynthesis of cholesterol. Although relatively safe and effective, the available statins can cause elevations in liver enzymes and myopathy. Squalene synthase is another enzyme that is downstream to HMG-CoA reductase in the cholesterol synthesis pathway and modulates the first committed step of hepatic cholesterol biosynthesis at the final branch point of the cholesterol biosynthetic pathway. Squalene epoxidase and oxidosqualene cyclase are other enzymes that act distally to squalene synthase. Pharmacologic inhibitors of these downstream enzymes have been developed, which may reduce low-density lipoprotein cholesterol and reduce the myopathy side effect seen with upstream inhibition of HMG-CoA. At this juncture, one squalene synthase inhibitor, lapaquistat (TAK-475) is in active clinical trials as a monotherapy, but there have been suggestions of increased hepatotoxicity with the drug.
Collapse
|
36
|
Quantitative Determination of Geranyl Diphosphate Levels in Cultured Human Cells. Lipids 2009; 44:1055-62. [DOI: 10.1007/s11745-009-3355-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2009] [Accepted: 09/28/2009] [Indexed: 12/22/2022]
|
37
|
Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs. Interdiscip Perspect Infect Dis 2009; 2009:642502. [PMID: 19680554 PMCID: PMC2721973 DOI: 10.1155/2009/642502] [Citation(s) in RCA: 131] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2009] [Accepted: 04/27/2009] [Indexed: 12/03/2022] Open
Abstract
Sterols are constituents of the cellular membranes that are essential for their normal structure and function. In mammalian cells, cholesterol is the main sterol found in the various membranes. However, other sterols predominate in eukaryotic microorganisms such as fungi and protozoa. It is now well established that an important metabolic pathway in fungi and in members of the Trypanosomatidae family is one that produces a special class of sterols, including ergosterol, and other 24-methyl sterols, which are required for parasitic growth and viability, but are absent from mammalian host cells. Currently, there are several drugs that interfere with sterol biosynthesis (SB) that are in use to treat diseases such as high cholesterol in humans and fungal infections. In this review, we analyze the effects of drugs such as (a) statins, which act on the mevalonate pathway by inhibiting HMG-CoA reductase, (b) bisphosphonates, which interfere with the isoprenoid pathway in the step catalyzed by farnesyl diphosphate synthase, (c) zaragozic acids and quinuclidines, inhibitors of squalene synthase (SQS), which catalyzes the first committed step in sterol biosynthesis, (d) allylamines, inhibitors of squalene epoxidase, (e) azoles, which inhibit C14α-demethylase, and (f) azasterols, which inhibit Δ24(25)-sterol methyltransferase (SMT). Inhibition of this last step appears to have high selectivity for fungi and trypanosomatids, since this enzyme is not found in mammalian cells. We review here the IC50 values of these various inhibitors, their effects on the growth of trypanosomatids (both in axenic cultures and in cell cultures), and their effects on protozoan structural organization (as evaluted by light and electron microscopy) and lipid composition. The results show that the mitochondrial membrane as well as the membrane lining the protozoan cell body and flagellum are the main targets. Probably as a consequence of these primary effects, other important changes take place in the organization of the kinetoplast DNA network and on the protozoan cell cycle. In addition, apoptosis-like and autophagic processes induced by several of the inhibitors tested led to parasite death.
Collapse
|
38
|
Huang ZR, Lin YK, Fang JY. Biological and pharmacological activities of squalene and related compounds: potential uses in cosmetic dermatology. Molecules 2009; 14:540-54. [PMID: 19169201 PMCID: PMC6253993 DOI: 10.3390/molecules14010540] [Citation(s) in RCA: 194] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2009] [Revised: 01/19/2009] [Accepted: 01/21/2009] [Indexed: 11/29/2022] Open
Abstract
Squalene is a triterpene that is an intermediate in the cholesterol biosynthesis pathway. It was so named because of its occurrence in shark liver oil, which contains large quantities and is considered its richest source. However, it is widely distributed in nature, with reasonable amounts found in olive oil, palm oil, wheat-germ oil, amaranth oil, and rice bran oil. Squalene, the main component of skin surface polyunsaturated lipids, shows some advantages for the skin as an emollient and antioxidant, and for hydration and its antitumor activities. It is also used as a material in topically applied vehicles such as lipid emulsions and nanostructured lipid carriers (NLCs). Substances related to squalene, including β-carotene, coenzyme Q10 (ubiquinone) and vitamins A, E, and K, are also included in this review article to introduce their benefits to skin physiology. We summarize investigations performed in previous reports from both in vitro and in vivo models.
Collapse
Affiliation(s)
- Zih-Rou Huang
- Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, 259 Wen-Hwa 1 Road, Kweishan, Taoyuan 333, Taiwan
| | - Yin-Ku Lin
- Graduate Institute of Clinical Medical Sciences, Chang Gung University, Kweishan, Taoyuan, Taiwan
- Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan
| | - Jia-You Fang
- Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, 259 Wen-Hwa 1 Road, Kweishan, Taoyuan 333, Taiwan
- Author to whom correspondence should be addressed: E-Mail: ; Tel.: +886-3-2118800 ext. 5521; Fax: +886-3-2118236
| |
Collapse
|
39
|
Do R, Kiss RS, Gaudet D, Engert JC. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Clin Genet 2009; 75:19-29. [DOI: 10.1111/j.1399-0004.2008.01099.x] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis 2009; 202:18-28. [DOI: 10.1016/j.atherosclerosis.2008.05.021] [Citation(s) in RCA: 84] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2007] [Revised: 05/13/2008] [Accepted: 05/13/2008] [Indexed: 12/18/2022]
|
41
|
Mota Júnior AO, Malavazi I, Soriani FM, Heinekamp T, Jacobsen I, Brakhage AA, Savoldi M, Goldman MHS, da Silva Ferreira ME, Goldman GH. Molecular characterization of the Aspergillus fumigatus NCS-1 homologue, NcsA. Mol Genet Genomics 2008; 280:483-95. [PMID: 18830711 DOI: 10.1007/s00438-008-0381-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2008] [Accepted: 09/03/2008] [Indexed: 12/23/2022]
Abstract
Here, we characterize the Aspergillus fumigatus homologue ncsA Neuronal Calcium Sensor. We showed that ncsA is not an essential gene and ncsA growth was decreased in the presence of EGTA and SDS. Furthermore, the ncsA mutant is more resistant to calcium chloride. NcsA:mRFP localizes to the cytoplasm and its cellular localization is not affected by the cellular response to either calcium chloride or EGTA. The ncsA mutant strain is more sensitive to voriconazole, itraconazole, and amphotericin. Polar growth in the DeltancsA mutant was also considerably more affected by lovastatin than in the wild type strain. The Spitzenkörper can be visualized in both strains and although the vacuolar system does not seem to be very different, there is an increase in the staining intensity on the germling surface of the ncsA strain. NcsA promotes pmcA and pmcB expression and therefore there is a reduced expression of these ion pumps in the DeltancsA mutant background, and also of other genes involved in the response to calcium in A. fumigatus. The ncsA inactivation mutation is not causing loss of virulence in a low dose murine infection when compared to the corresponding wild type strain.
Collapse
Affiliation(s)
- André Oliveira Mota Júnior
- Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects. Antimicrob Agents Chemother 2008; 52:4098-114. [PMID: 18765694 DOI: 10.1128/aac.01616-07] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
ER-119884 and E5700, novel arylquinuclidine derivatives developed as cholesterol-lowering agents, were potent in vitro growth inhibitors of both proliferative stages of Leishmania amazonensis, the main causative agent of cutaneous leishmaniasis in South America, with the 50% inhibitory concentrations (IC(50)s) being in the low-nanomolar to subnanomolar range. The compounds were very potent noncompetitive inhibitors of native L. amazonensis squalene synthase (SQS), with inhibition constants also being in the nanomolar to subnanomolar range. Growth inhibition was strictly associated with the depletion of the parasite's main endogenous sterols and the concomitant accumulation of exogenous cholesterol. Using electron microscopy, we identified the intracellular structures affected by the compounds. A large number of lipid inclusions displaying different shapes and electron densities were observed after treatment with both SQS inhibitors, and these inclusions were associated with an intense disorganization of the membrane that surrounds the cell body and flagellum, as well as the endoplasmic reticulum and the Golgi complex. Cells treated with ER-119884 but not those treated with E5700 had an altered cytoskeleton organization due to an abnormal distribution of tubulin, and many were arrested at cytokinesis. A prominent contractile vacuole and a phenotype typical of programmed cell death were frequently found in drug-treated cells. The selectivity of the drugs was demonstrated with the JC-1 mitochondrial fluorescent label and by trypan blue exclusion tests with macrophages, which showed that the IC(50)s against the host cells were 4 to 5 orders of magnitude greater that those against the intracellular parasites. Taken together, our results show that ER-119884 and E5700 are unusually potent and selective inhibitors of the growth of Leishmania amazonensis, probably because of their inhibitory effects on de novo sterol biosynthesis at the level of SQS, but some of our observations indicate that ER-119884 may also interfere with other cellular processes.
Collapse
|
43
|
Henneman L, van Cruchten AG, Denis SW, Amolins MW, Placzek AT, Gibbs RA, Kulik W, Waterham HR. Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem 2008; 383:18-24. [PMID: 18782552 DOI: 10.1016/j.ab.2008.08.023] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2008] [Revised: 08/20/2008] [Accepted: 08/25/2008] [Indexed: 11/26/2022]
Abstract
Isoprenoids constitute an important class of biomolecules that participate in many different cellular processes. Most available detection methods allow the identification of only one or two specific nonsterol isoprenoid intermediates following radioactive or fluorescent labeling. We here report a rapid, nonradioactive, and sensitive procedure for the simultaneous detection and quantification of the eight main nonsterol intermediates of the isoprenoid biosynthesis pathway by means of tandem mass spectrometry. Intermediates were analyzed by HPLC-MS/MS in the multiple reaction monitoring mode using a silica-based C(18) HPLC column. For quantification, their stable isotope-labeled analogs were used as internal standards. HepG2 cells were used to validate the method. Mevalonate, phosphomevalonate, and the six subsequent isoprenoid pyrophosphates were readily determined with detection limits ranging from 0.03 to 1.0mumol/L. The intra- and interassay variations for HepG2 cell homogenates supplemented with isoprenoid intermediates were 3.6-10.9 and 4.4-11.9%, respectively. Under normal culturing conditions, isoprenoid intermediates in HepG2 cells were below detection limits. However, incubation of the cells with pamidronate, an inhibitor of farnesyl pyrophosphate synthase, resulted in increased levels of mevalonate, isopentenyl pyrophosphate/dimethylallyl pyrophosphate, and geranyl pyrophosphate. This method will be suitable for measuring profiles of isoprenoid intermediates in cells with compromised isoprenoid biosynthesis and for determining the specificity of potential inhibitors of the pathway.
Collapse
Affiliation(s)
- Linda Henneman
- Academic Medical Center, University of Amsterdam, Laboratory Genetic Metabolic Diseases, Departments of Paediatrics/Emma Children's Hospital and Clinical Chemistry, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
BACKGROUND Many patients at high risk for coronary heart disease (CHD) fail to reach target lipid levels with currently available medications, and a small but clinically relevant proportion of patients experience adverse effects. Thus, additional pharmaceutical strategies are required to fill these gaps in efficacy and tolerability. OBJECTIVE To provide an overview of both current and emerging antidyslipidemic drugs. METHODS For the current antidyslipidemic drugs, we focus primarily on statins, bile acid sequestrants, fibrates, ezetimibe, and niacin. Emerging antidyslipidemic drugs herein discussed were identified by searching the Pharmaprojects database for 'hypercholesterolemia drugs' (Phase II or Phase III), 'HDL-based therapies', and 'PCSK9 inhibition'. RESULTS/CONCLUSIONS Combinations of currently existing medications are most easily applicable. Meanwhile, strategies to raise HDL-C rely on a deep understanding of the complexity of HDL metabolism. Furthermore, novel approaches to further reduce LDL-C warrant careful evaluation of benefit-risk ratio. Finally, the medical community will have to rely on late-phase CHD outcome studies as the final arbiter of clinical application for any new antidyslipidemia treatment.
Collapse
Affiliation(s)
- Rebecca L Pollex
- University of Western Ontario, Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, 100 Perth Drive, Room 406, London, Ontario, N6A 5K8 Canada
| | | | | |
Collapse
|
45
|
Elsayed RK, Evans JD. Emerging lipid-lowering drugs: squalene synthase inhibitors. Expert Opin Emerg Drugs 2008; 13:309-22. [DOI: 10.1517/14728214.13.2.309] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
46
|
Antiatherosclerotic Properties of EP2302, a Novel Squalene Synthase Inhibitor, in the Cholesterol-fed Rabbit. J Cardiovasc Pharmacol 2008; 51:573-80. [DOI: 10.1097/fjc.0b013e31817885fe] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Tong H, Wiemer AJ, Neighbors JD, Hohl RJ. Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue. Anal Biochem 2008; 378:138-43. [PMID: 18457649 DOI: 10.1016/j.ab.2008.04.021] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2008] [Revised: 04/09/2008] [Accepted: 04/11/2008] [Indexed: 11/27/2022]
Abstract
Farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP) are branch point intermediates of isoprenoid biosynthesis. Inhibitors of isoprenoid biosynthesis, such as the statins and bisphosphonates, are widely used therapeutic agents. However, little is known about the degree to which they alter levels of upstream and downstream isoprenoids, including FPP and GGPP. Therefore, we developed a method to isolate and quantify FPP and GGPP from mammalian tissues. Tissues from mice were collected, snap frozen in liquid nitrogen, and stored at -80 degrees C. FPP and GGPP were isolated by a combined homogenization and extraction procedure and were purified with a C18 solid phase extraction column. Farnesyl protein transferase (FTase) or geranylgeranyl protein transferase I (GGTase I) were used to conjugate FPP and GGPP with fluorescent dansylated peptides. FPP and GGPP were quantified by high-performance liquid chromatography (HPLC). The respective concentrations of FPP and GGPP are as follows: 0.355+/-0.030 and 0.827+/-0.082 units of nmol/g wet tissues in brain, 0.320+/-0.019 and 0.293+/-0.035 units of nmol/g wet tissues in kidney, 0.326+/-0.064 and 0.213+/-0.029 units of nmol/g wet tissues in liver, and 0.364+/-0.015 and 0.349+/-0.023 units of nmol/g wet tissues in heart (means+/-SEM). This method allows for determination of FPP and GGPP concentrations in any tissue type and is sensitive enough to detect changes following treatment with inhibitors of isoprenoid biosynthesis.
Collapse
Affiliation(s)
- Huaxiang Tong
- Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
| | | | | | | |
Collapse
|
48
|
Tavridou A, Megaritis G, Kourounakis AP, Charalambous A, Manolopoulos VG. EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells. ACTA ACUST UNITED AC 2008; 14:239-43. [PMID: 17922341 DOI: 10.1080/10623320701547216] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
EP2306 and EP2302 are two novel squalene synthase inhibitors with hypolipidemic, antiatherosclerotic, and antioxidant properties. In the present study, the authors investigated their effect on the expression and activity of endothelial nitric oxide synthase (eNOS) in cultured bovine aortic endothelial (BAE) cells and calf pulmonary artery endothelial (CPAE) cells. eNOS concentration was determined by immunoassay and eNOS activity by measuring the conversion of [(3)H]arginine to [(3)H]citrulline. Basal levels of eNOS in untreated BAE cells were 13.3 +/-1.6 ng/mg protein. Stimulation for 4 h with 30 microM of EP2306 or EP2302 resulted in increased eNOS protein level to 40% +/- 10% (p<.05) or 165% +/- 15% (p < .05) of unstimulated levels, respectively. Basal levels of eNOS in untreated CPAE cells were 3.4 +/- 0.4 ng/mg protein. Stimulation of CPAE cells for 4 h with 30 microM of EP2306 or EP2302 resulted in increased eNOS protein level to 195% +/- 24% (p < .05) and 152% +/- 19% (p < .05) of unstimulated levels, respectively. Despite their stimulatory action on eNOS expression, EP2300 compounds failed to induce any significant changes on eNOS enzymatic activity in BAE and CPAE cells. The finding that EP2300 compounds significantly increase the accumulation of eNOS in cultured endothelial cells sheds some light into their mechanism of action and supports a possible protective role of these compounds in atherosclerosis-related diseases.
Collapse
Affiliation(s)
- Anna Tavridou
- Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece
| | | | | | | | | |
Collapse
|
49
|
Lands B. A critique of paradoxes in current advice on dietary lipids. Prog Lipid Res 2007; 47:77-106. [PMID: 18177743 DOI: 10.1016/j.plipres.2007.12.001] [Citation(s) in RCA: 90] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2007] [Revised: 11/25/2007] [Accepted: 12/03/2007] [Indexed: 12/27/2022]
Abstract
Beliefs about credible hypotheses of dietary causes of disease still need well-defined mediators to test for logical proof or disproof. We know that food energy causes transient postprandial oxidative insults that may not be fully reversible. Also, eating vitamin-like 18-carbon polyunsaturated fatty acids (PUFA) in foods maintains the 20- and 22-carbon highly unsaturated fatty acids (HUFA) in tissues. Tissue HUFA form hormone-like mediators that each amplify transient postprandial insults into fatal inflammatory, thrombotic and arrhythmic events in cardiovascular disease, a major preventable cause of death. Similar diet-based amplified events may also occur in other inflammatory proliferative disorders including cancer, dementia, arthritis and asthma. Puzzling paradoxes come from fragmented views of this situation which convey incomplete knowledge in oversimplified messages. Tools now exist to demonstrate successful prevention of two fatal food imbalances with credible dietary preventive interventions, but organizers and financers to help gather the evidence remain unknown. The overall evidence accumulated about diet, disease and death may be nearing a paradigm shift in which prior observed facts remain while beliefs about their accepted interpretation change.
Collapse
Affiliation(s)
- Bill Lands
- 6100 Westchester Park Drive, #1219, College Park, MD 20740 USA.
| |
Collapse
|
50
|
Malavazi I, Savoldi M, da Silva Ferreira ME, Soriani FM, Bonato PS, de Souza Goldman MH, Goldman GH. Transcriptome analysis of the Aspergillus nidulans AtmA (ATM, Ataxia-Telangiectasia mutated) null mutant. Mol Microbiol 2007; 66:74-99. [PMID: 17880424 DOI: 10.1111/j.1365-2958.2007.05885.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
ATM is a phosphatidyl-3-kinase-related protein kinase that functions as a central regulator of DNA damage response in eukaryotes. In humans, mutations in ATM cause the devastating neurodegenerative disease Ataxia-Telangiectasia. Previously, we characterized the homologue of ATM (AtmA) in the filamentous fungus Aspergillus nidulans. In addition to its expected role in the DNA damage response, we found that AtmA is also required for polarized hyphal growth. Our results suggested that AtmA probably regulates the function and/or localization of landmark proteins required for the formation of a polarity axis. Here, we extended these studies by investigating which pathways are influenced by AtmA during proliferation and polar growth by comparatively determining the transcriptional profile of A. nidulans wild-type and DeltaatmA mutant strains in different growth conditions. Our results indicate an important role of the pentose phosphate pathway in the fungal proliferation during endogenous DNA damage and polar growth monitored by the AtmA kinase. Furthermore, we identified several genes that have decreased mRNA expression in the DeltaatmA mutant that are involved in the formation of a polarized hyphae and control of polar growth; in the synthesis of phosphatidic acid (e.g. phospholipase D); in the ergosterol biosynthesis (plasma membrane microdomains, lipid rafts); and in intracellular trafficking.
Collapse
Affiliation(s)
- Iran Malavazi
- Departamento de Ciências Farmacêuticas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil
| | | | | | | | | | | | | |
Collapse
|